Meta Pixel

News and Announcements

Make To Rent has received an investment from Accenture’s MD

  • Published July 09, 2021 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Vinod Patel, Managing Director at Accenture, has made the decision to back new residential property business Make To Rent. He will also become an advisor to the fund management team at Sturgeon Ventures, where he has a long-term business relationship with Make To Rent’s portfolio manager.

Register Interest

When asked, he commented that “whilst property is an illiquid asset class this project addresses many of the issues facing tenants in recent times, such as the ability to work from home and their all-round mental health”. He further comments that “the correlation of investor success to management reward is also a powerful message”.

Sturgeon Ventures Portfolio Manager, Tim Peppiatt, commented, “having somebody of Vinod’s ability and gravitas invest, and become an advisor, will be hugely beneficial as we grow”. We have already seen a significant uptick in activity, with both investors and introducers wanting greater volumes of information. Communication and organisation at scale is something he has vast experience with and I’m sure will prove invaluable to us.

About Make to Rent

The simplest way to understand Make To Rent as an investor is to draw a comparison to WeWork, the serviced office provider. The fundamental difference being that our investors capital will be used to construct or purchase discounted assets in order to create superior asset growth and returns, not just leases. Make To Rent’s focus from the outset has been on regulatory compliance, the visibility of application for our investors’ funds, and the alignment of management rewards to performance. Raising funds in advance enables Make To Rent to move more quickly than others when advantageous opportunities present themselves.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now